|
EQS Voting Rights Announcement: MorphoSys AG
MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
12.04.2024 / 16:04 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification pursuant to Section 43 (1) WpHG
In accordance with Section 43 para. 1 sentences 1, 3 and 4 German Securities Trading Act (WpHG), Kynam Capital Management, LP notified MorphoSys AG as follows regarding the goals pursued by the acquisition of voting rights and the sources of funds:
- The investment by Kynam Capital Management, LP serves to generate trading profits
- Kynam Capital Management, LP plans to acquire further voting rights within the next twelve months by means of a purchase (but reserves the right to refrain from doing so in the future).
- Kynam Capital Management, LP does not intend to exert influence on the appointment or removal of members of the issuer’s administrative, managing and/or supervisory bodies, and
- Kynam Capital Management, LP does not intend to achieve a material change in the company’s capital structure, in particular as regards the ratio between equity and debt and the dividend policy
- The acquisition of the shares in the company by Kynam Capital Management, LP and Kynam Global Healthcare Master Fund, LP was financed by equity.
12.04.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
MorphoSys AG |
|
Semmelweisstr. 7 |
|
82152 Planegg |
|
Germany |
| Internet: |
www.morphosys.com |
| |
| End of News |
EQS News Service |
1879467 12.04.2024 CET/CEST
Ausgewählte Hebelprodukte auf MorphoSys
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen
partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen
passende Open-End Produkte auf MorphoSys
Der Hebel muss zwischen 2 und 20 liegen
Risikohinweis: Im Durchschnitt erleiden
7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten.
Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige
Anlagestrategien geeignet.
Risikohinweis: Im Durchschnitt erleiden
7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten.
Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige
Anlagestrategien geeignet.
Werbung
anmelden
